ClinicalTrialsFinder

RecruitingPhase 1Phase 2NCT06618287

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors

Sponsor

Bristol-Myers Squibb

Enrollment

416 participants

Start Date

Feb 4, 2025

Study Type

INTERVENTIONAL

Conditions

Breast Cancer Lung Cancer

Summary

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing BMS-986507 in combination with other targeted therapies for people with advanced solid tumors. BMS-986507 is designed to block a protein that helps cancer cells evade the immune system. Different groups in the study focus on specific cancer types with specific mutations, including non-small cell lung cancer (NSCLC) with EGFR mutations and other advanced solid tumors. **You may be eligible if...** - You are in good general health (ECOG score 0–1) - You have at least one measurable tumor - Your life expectancy is at least 3 months - Group A: you have advanced NSCLC with specific EGFR mutations (exon 19 deletion or L858R in exon 21, or other EGFR mutations) - Group B: you have another type of advanced solid tumor meeting the specific group criteria - Your organ function is adequate **You may NOT be eligible if...** - You have active, uncontrolled brain metastases - You have significant autoimmune disease or prior severe immune-related side effects - Your organ function does not meet required levels Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBMS-986507

Specified dose on specified days

DRUGOsimertinib

Specified dose on specified days

DRUGPembrolizumab

Specified dose on specified days

DRUGNivolumab

Specified dose on specified days

DRUGPumitamig

Specified dose on specified days

Locations(63)

University of Alabama at Birmingham

Birmingham, Alabama, United States

University of Miami Hospital and Clinics, Sylvester Cancer Center

Miami, Florida, United States

Local Institution - 0125

Maywood, Illinois, United States

Local Institution - 0065

Iowa City, Iowa, United States

John Theurer Cancer Center at Hackensack University Medical Center

Hackensack, New Jersey, United States

Cleveland Clinic

Cleveland, Ohio, United States

Local Institution - 0102

Columbus, Ohio, United States

Local Institution - 0052

Portland, Oregon, United States

Local Institution - 0090

Portland, Oregon, United States

Local Institution - 0014

Pittsburgh, Pennsylvania, United States

Local Institution - 0103

Knoxville, Tennessee, United States

Local Institution - 0092

Irving, Texas, United States

Swedish Medical Center

Seattle, Washington, United States

Liverpool Hospital

Liverpool, New South Wales, Australia

Princess Alexandra Hospital

Woolloongabba, Queensland, Australia

Local Institution - 0108

East Melbourne, Victoria, Australia

Local Institution - 0101

Subiaco, Western Australia, Australia

Cross Cancer Institute

Edmonton, Alberta, Canada

Local Institution - 0064

Newmarket, Ontario, Canada

Local Institution - 0023

Ottawa, Ontario, Canada

The Ottawa Hospital - General Campus

Ottawa, Ontario, Canada

Centre Hospitalier de l'Université de Montréal

Montreal, Quebec, Canada

Jewish General Hospital

Montreal, Quebec, Canada

Local Institution - 0105

Valdivia, Los Ríos Region, Chile

Local Institution - 0048

Santiago, Santiago Metropolitan, Chile

Local Institution - 0049

Santiago, Santiago Metropolitan, Chile

Local Institution - 0047

Santiago, Santiago Metropolitan, Chile

Local Institution - 0107

Viña del Mar, Valparaiso, Chile

Local Institution - 0077

Nice, Alpes-Maritimes, France

Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest

Bordeaux, Aquitaine, France

Centre Leon Berard

Lyon, Auvergne-Rhône-Alpes, France

Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone

Marseille, Bouches-du-Rhône, France

Local Institution - 0076

Caen, Calvados, France

Hôpital Arnaud de Villeneuve - CHU Montpellier

Montpellier, Hérault, France

Gustave Roussy

Villejuif, Val-de-Marne, France

Institut Curie

Paris, France

Hôpital Tenon

Paris, France

Cro-Irccs

Aviano, Friuli Venezia Giulia, Italy

Fondazione IRCCS Istituto Nazionale dei Tumori

Milan, Lombardy, Italy

Istituto di Candiolo IRCCS - Fondazione del Piemonte per l'Oncologia

Candiolo, Torino, Italy

Azienda Ospedaliera Universitaria Careggi

Florence, Tuscany, Italy

Local Institution - 0110

Ancona, Italy

Local Institution - 0093

Milan, Italy

Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore

Roma, Italy

Leids Universitair Medisch Centrum

Leiden, South Holland, Netherlands

Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL)

Amsterdam, Netherlands

CHUS - Hospital Clinico Universitario

Santiago de Compostela, A Coruña [La Coruña], Spain

Hospital Universitari Vall d'Hebron

Barcelona, Barcelona [Barcelona], Spain

Institut Català d'Oncologia - L'Hospitalet

Hospitalet, Barcelona [Barcelona], Spain

Local Institution - 0059

Barcelona, Catalunya [Cataluña], Spain

Hospital Universitario 12 de Octubre

Madrid, Madrid, Comunidad de, Spain

Hospital Universitario Puerta de Hierro Majadahonda

Majadahonda, Madrid, Comunidad de, Spain

Local Institution - 0118

Valencia, Valenciana, Comunitat, Spain

Hospital Universitario Fundación Jiménez Díaz

Madrid, Spain

Local Institution - 0127

Madrid, Spain

Hospital Universitario HM Sanchinarro

Madrid, Spain

H.R.U Málaga - Hospital General

Málaga, Spain

Local Institution - 0112

Seville, Spain

Hospital Universitari i Politecnic La Fe

Valencia, Spain

Royal Free Hospital

London, England, United Kingdom

Local Institution - 0021

Glasgow, Glasgow City, United Kingdom

University Hospitals Birmingham NHS Foundation Trust

Birmingham, West Midlands, United Kingdom

Local Institution - 0001

Newcastle upon Tyne, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

NCT06618287

Related Trials

Genomic Services Research Program

NCT025959571 location

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

NCT052833304 locations

A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)

NCT070671381 location

Social and Environmental Determinants of Breast Cancer Survivorship: the Black Breast Cancer Survivor's Intervention (BBCSI)

NCT068852031 location

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

NCT06103864316 locations